Vir Biotechnology Appoints David Liu as Chief Medical Officer
Vir Biotechnology (VIR) announced on Wednesday that it has appointed David Liu as executive vice president and chief medical officer, effective October 12, 2026. In this role, Liu will oversee clinical development, medical affairs, and regulatory functions for the company. The appointment is expected to strengthen Vir's leadership in advancing its pipeline of therapeutic candidates through clinical trials and toward regulatory approval. The addition of a high-profile executive like Liu may signal confidence among investors regarding the company’s strategic direction and future growth potential.
Tickers: $VIR